Price Alert

Aurinia Pharmaceuticals I... (AUPH)

NASDAQ: AUPH · Real-Time Price · USD

12.43

0.34 (2.81%)

At close: Aug 15, 2025, 2:33 PM

2.81% (1D)

Bid	12.43
Market Cap	1.64B
Revenue (ttm)	260.11M
Net Income (ttm)	60.64M
EPS (ttm)	0.43
PE Ratio (ttm)	28.91
Forward PE	14.98
Analyst	Buy

Ask	12.44
Volume	1,387,018
Avg. Volume (20D)	1,998,501
Open	12.14
Previous Close	12.09
Day's Range	12.12 - 12.48
52-Week Range	5.51 - 12.48
Beta	1.24

About AUPH

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol AUPH

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for AUPH stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

Aurinia Pharmaceuticals Inc. is scheduled to release its earnings on Nov 6, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

9 months ago

+10.9%

Aurinia Pharmaceuticals shares are trading higher ... Unlock content with Pro Subscription

11 months ago

+0.77%

Aurinia Pharmaceuticals shares are trading higher after the company announced a board restructuring consisting of seven members.

News

1 week ago · seekingalpha.com

Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade)

Aurinia Pharmaceuticals Inc. reported total revenues of $70M in Q2 '25, aided by record Lupkynis net product sales of $66.6M. AUPH management continues to execute well, maintaining positive cash flow,...

1 week ago · zacks.com

Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 weeks ago · fool.com

Aurinia (AUPH) Q2 Revenue Jumps 22%

Aurinia Pharmaceuticals (AUPH 2.15%), a biopharmaceutical company focused on therapies for autoimmune diseases, released its second-quarter 2025 earnings on July 31, 2025. The headline news: revenue (...

2 weeks ago · seekingalpha.com

Aurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call Transcript

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Gregory F. Keenan - Chief Medical Officer Joseph M.

2 weeks ago · zacks.com

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.16 per share, missing the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.02 per share a year ago.

2 weeks ago · businesswire.com

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025

ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025.

3 weeks ago · businesswire.com

Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025.

1 month ago · seekingalpha.com

The Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides Opportunity

I revisit biopharma name Aurinia Pharmaceuticals Inc. for the first time in 2025 after the company reported solid Q1 results in May. The quarter saw Lupkynis net product revenues up 25% year-over-year...

1 month ago · https://www.marketscreener.com

Aurinia Pharmaceuticals Inc. - Special Call

Presentation Operator MessageOperator (Operator)Good morning, and welcome to Aurinia's Aritinercept Phase I Study Results Conference Call. [Operator Instructions]

1 month ago · businesswire.com

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200).

Load More News